Natural Antioxidants Reduce Oxidative Stress and the Toxic Effects of RNA-CUG(exp) in an Inducible Glial Myotonic Dystrophy Type 1 Cell Model
- PMID: 40227219
- PMCID: PMC11939792
- DOI: 10.3390/antiox14030260
Natural Antioxidants Reduce Oxidative Stress and the Toxic Effects of RNA-CUG(exp) in an Inducible Glial Myotonic Dystrophy Type 1 Cell Model
Abstract
The toxic gain-of-function of RNA-CUG(exp) in DM1 has been largely studied in skeletal muscle, with little focus on its effects on the central nervous system (CNS). This study aimed to study if oxidative stress is present in DM1, its relationship with the toxic RNA gain-of-function and if natural antioxidants can revert some of the RNA-CUG(exp) toxic effects. Using an inducible glial DM1 model (MIO-M1 cells), we compared OS in expanded vs. unexpanded cells and investigated whether antioxidants can mitigate OS and RNA-CUG(exp) toxicity. OS was measured via superoxide anion and lipid peroxidation assays. RNA foci were identified using FISH, and the mis-splicing of selected exons was analyzed using semi-quantitative RT-PCR. Cells were treated with natural antioxidants, and the effects on OS, foci formation, and mis-splicing were compared between treated and untreated cells. The results showed significantly higher superoxide anion and lipid peroxidation levels in untreated DM1 cells, which decreased after antioxidant treatment (ANOVA, p < 0.001). Foci were present in 51% of the untreated cells but were reduced in a dose-dependent manner following treatment (ANOVA, p < 0.001). Antioxidants also improved the splicing of selected exons (ANOVA, p < 0.001), suggesting OS plays a role in DM1, and antioxidants may offer therapeutic potential.
Keywords: RNA toxic gain-of-function; antioxidants; glial cell model; inducible model; myotonic dystrophy; treatment.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures






Similar articles
-
Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.Biomolecules. 2021 Jan 26;11(2):159. doi: 10.3390/biom11020159. Biomolecules. 2021. PMID: 33530452 Free PMC article.
-
Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy.Ann Clin Transl Neurol. 2015 Dec 10;3(1):42-54. doi: 10.1002/acn3.271. eCollection 2016 Jan. Ann Clin Transl Neurol. 2015. PMID: 26783549 Free PMC article.
-
Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.ACS Chem Biol. 2018 Sep 21;13(9):2708-2718. doi: 10.1021/acschembio.8b00646. Epub 2018 Aug 27. ACS Chem Biol. 2018. PMID: 30118588 Free PMC article.
-
Short Tandem Repeat Expansions and RNA-Mediated Pathogenesis in Myotonic Dystrophy.Int J Mol Sci. 2019 Jul 9;20(13):3365. doi: 10.3390/ijms20133365. Int J Mol Sci. 2019. PMID: 31323950 Free PMC article. Review.
-
The hallmarks of myotonic dystrophy type 1 muscle dysfunction.Biol Rev Camb Philos Soc. 2021 Apr;96(2):716-730. doi: 10.1111/brv.12674. Epub 2020 Dec 2. Biol Rev Camb Philos Soc. 2021. PMID: 33269537 Review.
References
-
- Harper P.S. Myotonic Dystrophy. 2nd ed. W B Saunders Company; Philadelphia, PA, USA: 1989.
Grants and funding
LinkOut - more resources
Full Text Sources